Leerink Partnrs Predicts Nkarta FY2024 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Research analysts at Leerink Partnrs issued their FY2024 earnings estimates for Nkarta in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($1.77) per share for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Nkarta’s Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($1.86) EPS.

Other research analysts have also issued reports about the stock. Mizuho dropped their price objective on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. HC Wainwright decreased their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Finally, Needham & Company LLC decreased their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Nkarta presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Stock Up 2.7 %

NASDAQ NKTX opened at $2.27 on Monday. The company has a fifty day moving average of $2.34 and a two-hundred day moving average of $3.53. The firm has a market capitalization of $160.19 million, a price-to-earnings ratio of -1.21 and a beta of 0.85. Nkarta has a 52 week low of $1.96 and a 52 week high of $16.24.

Hedge Funds Weigh In On Nkarta

A number of large investors have recently added to or reduced their stakes in NKTX. The Manufacturers Life Insurance Company raised its holdings in Nkarta by 92.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock worth $122,000 after purchasing an additional 9,975 shares in the last quarter. SG Americas Securities LLC bought a new position in Nkarta in the third quarter worth about $93,000. Intech Investment Management LLC bought a new position in Nkarta in the third quarter worth about $74,000. FMR LLC raised its holdings in Nkarta by 97.1% in the third quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after purchasing an additional 65,600 shares in the last quarter. Finally, Wasatch Advisors LP raised its holdings in Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after purchasing an additional 442,125 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors.

Insider Activity at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.70% of the stock is currently owned by corporate insiders.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.